115 related articles for article (PubMed ID: 10951431)
1. Pharmacokinetics of cisplatin in analbuminemic rats.
Takada K; Kawamura T; Inai M; Masuda S; Oka T; Yoshikawa Y; Shibata N; Yoshikawa H; Ike O; Wada H; Hitomi S
Biopharm Drug Dispos; 1999 Dec; 20(9):421-8. PubMed ID: 10951431
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of intravenous bumetanide in mutant Nagase analbuminemic rats: importance of globulin binding for the pharmacodynamic effects.
Kim EJ; Lee MG
Biopharm Drug Dispos; 2001 May; 22(4):147-56. PubMed ID: 11745917
[TBL] [Abstract][Full Text] [Related]
3. Contribution of plasma proteins, albumin and alpha 1-acid glycoprotein, to pharmacokinetics of a multi-targeted receptor tyrosine kinase inhibitor, sunitinib, in analbuminemic rats.
Toyama Y; Ueyama J; Nomura H; Tsukiyama I; Saito H; Hisada T; Matsuura K; Hasegawa T
Anticancer Res; 2014 May; 34(5):2283-9. PubMed ID: 24778032
[TBL] [Abstract][Full Text] [Related]
4. Effects of a cisplatin-chondroitin sulfate A complex in reducing the nephrotoxicity of cisplatin.
Zhang JS; Imai T; Otagiri M
Arch Toxicol; 2000 Aug; 74(6):300-7. PubMed ID: 11005675
[TBL] [Abstract][Full Text] [Related]
5. Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients.
Nagai N; Kinoshita M; Ogata H; Tsujino D; Wada Y; Someya K; Ohno T; Masuhara K; Tanaka Y; Kato K; Nagai H; Yokoyama A; Kurita Y
Cancer Chemother Pharmacol; 1996; 39(1-2):131-7. PubMed ID: 8995510
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II) and cisplatin given i.v. and i.p. in the rat.
Vadiei K; Siddik ZH; Khokhar AR; al-Baker S; Sampedro F; Perez-Soler R
Cancer Chemother Pharmacol; 1992; 30(5):365-9. PubMed ID: 1505075
[TBL] [Abstract][Full Text] [Related]
7. Quantitative relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity in rats: importance of area under the concentration-time curve (AUC) as the major toxicodynamic determinant in vivo.
Nagai N; Ogata H
Cancer Chemother Pharmacol; 1997; 40(1):11-8. PubMed ID: 9137523
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of intravenous trasemide in mutant Nagase analbuminemic rats.
Kim EJ; Lee MG
Biopharm Drug Dispos; 2003 Jan; 24(1):27-35. PubMed ID: 12516076
[TBL] [Abstract][Full Text] [Related]
9. Transhepatic transport of taurocholic acid in normal and mutant analbuminemic rats.
Inoue M; Morino Y; Nagase S
Biochim Biophys Acta; 1985 Feb; 833(2):211-6. PubMed ID: 3970952
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin pharmacokinetics and its nephrotoxicity in diabetic rabbits.
Najjar TA; Saad SY
Chemotherapy; 2001; 47(2):128-35. PubMed ID: 11173815
[TBL] [Abstract][Full Text] [Related]
11. Effects of sodium thiosulfate on the pharmacokinetics of unchanged cisplatin and on the distribution of platinum species in rat kidney: protective mechanism against cisplatin nephrotoxicity.
Nagai N; Hotta K; Yamamura H; Ogata H
Cancer Chemother Pharmacol; 1995; 36(5):404-10. PubMed ID: 7634382
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of intravenous azosemide in mutant Nagase analbuminemic rats.
Kim EJ; Lee AK; Kim SH; Kim SG; Lee MG
Drug Metab Dispos; 2003 Feb; 31(2):194-201. PubMed ID: 12527700
[TBL] [Abstract][Full Text] [Related]
13. Effects of disopyramide and verapamil on renal disposition and nephrotoxicity of cisplatin in rats.
Hanada K; Odaka K; Kudo A; Ogata H
Pharm Res; 1999 Oct; 16(10):1589-95. PubMed ID: 10554102
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, biodistribution and in vivo efficacy of cisplatin loaded poly(L-glutamic acid)-g-methoxy poly(ethylene glycol) complex nanoparticles for tumor therapy.
Yu H; Tang Z; Zhang D; Song W; Zhang Y; Yang Y; Ahmad Z; Chen X
J Control Release; 2015 May; 205():89-97. PubMed ID: 25529533
[TBL] [Abstract][Full Text] [Related]
15. Binding kinetics of tetrachloro-1,2-diaminocyclohexaneplatinum (IV) (tetraplatin) and cis-diamminedichloroplatinum (II) at 37 degrees C with human plasma proteins and with bovine serum albumin. Does aquation precede protein binding?
LeRoy AF; Thompson WC
J Natl Cancer Inst; 1989 Mar; 81(6):427-36. PubMed ID: 2918550
[TBL] [Abstract][Full Text] [Related]
16. Further observations on the disposition characteristics of salicylic acid in analbuminemic rats.
Hirate J; Kato Y; Horikoshi I; Nagase S; Ueda CT
Biopharm Drug Dispos; 1989; 10(3):299-309. PubMed ID: 2720133
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics and pharmacodynamics of cisplatin in patients with cancer: analysis with the NONMEM program.
Nagai N; Ogata H; Wada Y; Tsujino D; Someya K; Ohno T; Masuhara K; Tanaka Y; Takahashi H; Nagai H; Kato K; Koshiba Y; Igarashi T; Yokoyama A; Kinameri K; Kato T; Kurita Y
J Clin Pharmacol; 1998 Nov; 38(11):1025-34. PubMed ID: 9824784
[TBL] [Abstract][Full Text] [Related]
18. Perinatal changes of alpha-fetoprotein concentration in the serum and its synthesis in the liver of analbuminemic rats.
Esumi H; Takahashi Y; Seki M; Sato S; Nagase S; Sugimura T
Cancer Res; 1982 Jan; 42(1):306-8. PubMed ID: 6172194
[TBL] [Abstract][Full Text] [Related]
19. Disposition of salicylic acid in analbuminemic rats.
Hirate J; Horikoshi I; Watanabe J; Ozeki S; Nagase S
J Pharmacobiodyn; 1984 Dec; 7(12):929-34. PubMed ID: 6533283
[TBL] [Abstract][Full Text] [Related]
20. Disposition of phenytoin in analbuminemic rats.
Hirate J; Horikoshi I; Nagase S
Biopharm Drug Dispos; 1990 Dec; 11(9):773-83. PubMed ID: 2271753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
